EHMA`s aim is to improve the quality and build the capacity of health management across the European region. As EHMA`s statutes state: we seek to "improve health management and health policies through the development and exchange of both ideas and practices among academics, researchers, managers, clinicians, policy makers and consumers throughout Europe."

EHMA structures its vision under three areas: Quality and Equity in health and healthcare; Innovation in health management; and Sustainable Health Systems; underpinned in all three areas by Leadership.

> Quality and Equity: We want to see high quality healthcare and reduced health inequalities, led by outstanding managers, supported by appropriate policy frameworks and underpinned by the best available research.

> Innovation: We want to see innovative health management and research that thinks radically about service provision and public health for the good of all citizens.

> Sustainable health systems: We want to see health systems equipped to respond to current and future challenges in a way that safeguards health for all.




The paramount objective of the "Chain of Trust" project is to advance the empowerment of patients, health professionals and national health authorities across the EU in their understanding and effective use of telehealth services in an effort to actively contribute to the vision of high quality, patient-centred, equitable healthcare for all EU patients.
Through a series of focused and well defined actions the project will strengthen significantly the levels of awareness and trust for all key stakeholders.

To this end two specific objectives have been identified:

1. Knowledge gathering. To improve available knowledge of the specific views – needs, perceptions on the added value and concerns - among patients and health professionals with regard to telehealth services;

2. Rasing awareness and understanding. To increase awareness and understanding of users` perspective on telehealth amongst patients` and health professionals` organisations and health authorities at European and Member State level.


Human exposure to manufactured nanomaterials (MNs) used in consumer products may occur during several phases of their life cycle. The lack of scientific knowledge makes regulation difficult.

The aim of the Joint Action is to establish a robust methodology to assess the potential genotoxicity of MNs and to generate data on the genotoxic effect of certain reference materials (www.nanogenotox.eu).

The JA specific objectives are:
To obtain detailed physicochemical properties for each selected MN
To determine the influence of exposure media on MNs dispersability and to identify the optimum preparation protocols for the specific MNs
To generate in vitro genotoxicity data on MNs
To perform a round robin test on in vitro genotoxicity testing of MNs
To determine relevant doses and sampling time for biodistribution and in vivo genotoxicity studies, and to identify MN accumulation in organs for in vivo genotoxicity tests
To generate data from in vivo genotoxicity selected tests, and to assess the correlation between in vivo and in vitro results taking into account the kinetic results
